Compare Matson Inc (MATX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Matson Inc vs Recursion Pharmaceuticals Inc — how do they compare? Matson Inc trades at $229 (market cap $6.67B), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.31B). The key difference: Matson Inc is far larger — about 2.9× Recursion Pharmaceuticals Inc's market cap, and Matson Inc pays a 0.68% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Matson Inc for 23 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| MATX | RXRX | |
|---|---|---|
Market Cap | $6.67B | $2.31B |
Volume | 233,711 | 40,478,768 |
Sector | Industrials | Health |
52-Week High | $238.60 | $6.79 |
52-Week Low | $88.05 | $2.84 |
Typical Hold Time | 23 Days | 22 Days |
Enterprise Value | $7.26B | $1.83B |
Dividend Yield | 0.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Matson (MATX) trades at $222.92, down 0.83% today, with neutral technical signals and strong fundamental performance. The stock shows robust earnings momentum with three consecutive quarterly beats, including Q2 2026 EPS of $4.27 versus $3.79 expected. Revenue growth continues with 2026 projections reaching $3.5 billion, supported by a 13.4% net income margin. Recent news highlights institutional buying interest and positive analyst sentiment.
MATX presents a compelling investment case with solid profitability metrics and analyst support, though near-term technical resistance at $224 may limit upside. The company's raised full-year outlook and consistent dividend payments provide stability, while exposure to freight market volatility remains a key risk factor for shareholders.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
